However, Tumeh et al. [40] found that patients with liver metastasis of melanoma or non-small cell lung cancer who were treated with pembrolizumab showed reduced response and PFS and that liver metastasis was associated with reduced marginal CD8 + T-cell infiltration, providing a potential mechanism for the worse prognosis. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.